DSGN at a glance
Design Therapeutics, Inc. (DSGN, SEC CIK 1807120) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and Form 4 insider filings as recently as June 11, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Design Therapeutics, Inc. (DSGN) reported revenue of $0 and a net loss of $69.8 million. Diluted EPS was -$1.22.
- As of June 30, 2026, 27 institutional investment managers tracked by SignalX reported holding Design Therapeutics, Inc. (DSGN) shares worth $145.5 million in 13F-HR filings.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $0
- 10-K XBRL
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 27 funds
- $145.5M · +0 vs prior quarter
- Latest 8-K
- Aug 3, 2026
- Item 2.02
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- No explicit new risk factor identified; section contains carried-forward risks without a stated “no material changes” disclosure
- DT-216 development shifted from DT-216P1 to DT-216P2 after injection-site thrombophlebitis in five MAD-trial patients
- FDA clinical-hold risk for DT-216P2; hold lifted December 2025 after clearance to initiate clinical studies
- Clinical-stage execution risk; DT-818 Phase 1 MAD results anticipated in 2027
- Funding risk; $207.4 million in cash, cash equivalents and investment securities expected to fund operations for more than 12 months
AI summary of the DSGN 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Design Therapeutics reported financial results for Q2 and six months ended June 30, 2026
- Results detailed in Exhibit 99.1, the company’s accompanying earnings press release
Item EX-99.1: Item EX-99.1
- Q2 net loss $20.2M, or $0.32 per share, with R&D spending of $16.4M
- Cash and securities $207.4M at June 30, down from $219.8M at December 31
Item 5.07: Submission of Matters to a Vote of Security Holders
- Simeon George, M.D. elected Class II director through 2029 annual meeting
- Director vote: 29,205,208 for, 7,608,724 withheld, 13,264,883 broker non-votes
Item 8.01: Other Events
- Phase 1/2 RESTORE-FA data support DT-216P2 activity in Friedreich ataxia after four weeks across 16 treated patients
- At 1 mpk, mean improvements reached 6.4 points on mFARS and 2.7 points on Upright Stability Score
AI summaries of DSGN 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for DSGN
Don't miss the next DSGN filing
- Alerts as it files. A push when DSGN files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut DSGN, by share count.
- Ask anything. An AI agent that reads every DSGN filing and answers with sources.
DSGN alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Schmid John P. | A | Jun 9, 2026 | 30,000 | - |
| Berger Heather A. | A | Jun 9, 2026 | 30,000 | - |
| Gover Justin D. | A | Jun 9, 2026 | 30,000 | - |
| LAPPE RODNEY W | A | Jun 9, 2026 | 30,000 | - |
| Shapiro David | A | Jun 9, 2026 | 30,000 | - |
| George Simeon | A | Jun 9, 2026 | 30,000 | - |
| Shapiro David | A | Mar 31, 2026 | 60,000 | - |
| Shapiro David | A | Mar 31, 2026 | 7,500 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $0 | $0 |
| Operating Income | -$78.2M | -$62.4M | -$79.5M |
| Net Income | -$66.9M | -$49.6M | -$69.8M |
| Balance Sheet | |||
| Total Assets | - | $252.1M | $226.2M |
| Equity | $277.7M | $242.1M | $212.5M |
| ROE | -24.1% | -20.5% | -32.8% |
| Per Share | |||
| EPS | - | $-0.88 | $-1.22 |
| Cash Flow | |||
| Operating CF | -$58.6M | -$43.1M | -$54.4M |
| CapEx | - | $340K | $193K |
Source: XBRL data in Design Therapeutics, Inc. (DSGN)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate DSGN share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 27 | $145.5M |
| Q1 2026 | 27 | $92.7M |
| Q4 2025 | 25 | $83.9M |
| Q3 2025 | 23 | $56.3M |
| Q2 2025 | 22 | $28.8M |
| Q1 2025 | 20 | $24.6M |
| Q4 2024 | 15 | $36.2M |
| Q3 2024 | 14 | $18.0M |
- BlackRock+526.3K (+25%)
- Dimensional Fund Advisors+262.9K (+61%)
- Vanguard Capital Management LLC+221.2K (+16%)
- Prudential Financial+178.4K (+389%)
- Goldman Sachs Group+151.9K (+30%)
- D.E. Shaw & Co−274.6K (-58%)
- Citadel Advisors LLC−149.5K (-65%)
- Invesco Ltd−120.5K (-85%)
- FMR LLC (Fidelity)−21.9K (-3%)
- Renaissance Technologies LLC−20.3K (-5%)
Source: 13F-HR filings on SEC EDGAR (aggregated from 173 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
DSGN filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| SC 13G | Aug 14, 2026 | - | - | |
| 10-Q | Aug 3, 2026 | Jun 30, 2026 | Analysis | |
| 8-K | Aug 3, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 8-K | Jun 11, 2026 | - | Analysis | - |
| 4 | Jun 11, 2026 | - | - | - |
| SC 13G | Jun 9, 2026 | - | - | |
| 8-K | May 18, 2026 | - | Analysis | |
| 10-Q | Apr 28, 2026 | Mar 31, 2026 | Analysis | |
| 8-K | Apr 28, 2026 | - | Analysis | - |
| 8-K | Apr 1, 2026 | - | - | - |
| 4 | Apr 1, 2026 | - | - | - |
| 10-K | Mar 9, 2026 | Dec 31, 2025 | - | |
| 8-K | Mar 9, 2026 | - | Analysis | - |
| 8-K | Jan 30, 2026 | - | - | |
| 4 | Jan 5, 2026 | - | - | |
| 4 | Jan 5, 2026 | - | - | |
| 4 | Jan 5, 2026 | - | - | |
| 4 | Jan 5, 2026 | - | - | |
| 4 | Jan 5, 2026 | - | - | |
| 4 | Dec 11, 2025 | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
DSGN SEC filings: frequently asked questions
Which institutions hold DSGN stock?
As of June 30, 2026, the largest Design Therapeutics, Inc. (DSGN) holders among the 13F filers tracked by SignalX were BlackRock ($38.5 million), Vanguard Capital Management LLC ($22.7 million), FMR LLC (Fidelity) ($11.2 million), Morgan Stanley ($11.1 million), State Street Corp ($10.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was DSGN's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Design Therapeutics, Inc. (DSGN) reported revenue of $0 and a net loss of $69.8 million. Diluted EPS was -$1.22. The figures come from the XBRL data in the 10-K.
What did DSGN report in its latest 8-K?
Design Therapeutics, Inc. (DSGN) filed an 8-K on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Design Therapeutics reported financial results for Q2 and six months ended June 30, 2026.
What are the latest DSGN SEC filings?
Design Therapeutics, Inc. (DSGN) filed its latest 10-K annual report on March 9, 2026, a 10-Q quarterly report on August 3, 2026, an 8-K current report on August 3, 2026 and a Form 4 insider filing on June 11, 2026.
What is DSGN's SEC CIK number?
Design Therapeutics, Inc. (DSGN)'s SEC Central Index Key (CIK) is 1807120. EDGAR lists every DSGN filing under that number.
Ask anything about DSGN
The research agent reads DSGN's filings, financials, insider trades and 13F holders, then answers with sources.